Affordable Access

deepdyve-link deepdyve-link
Publisher Website

A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.

Authors
  • Fury, Matthew G
  • Haque, Sofia
  • Stambuk, Hilda
  • Shen, Ronglai
  • Carlson, Diane
  • Pfister, David
Type
Published Article
Journal
Cancer
Publication Date
Feb 15, 2011
Volume
117
Issue
4
Pages
795–801
Identifiers
DOI: 10.1002/cncr.25464
PMID: 20922785
Source
Medline
License
Unknown

Abstract

Treatment with pemetrexed plus gemcitabine every 2 weeks with vitamin support generally was well tolerated. The results of this study provided further evidence that pemetrexed may have significant palliative activity against advanced HNSCC.

Report this publication

Statistics

Seen <100 times